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Abstract  25 
Background: Pregnant women have an increased risk for complications and hospitalizations 26 
when infected with the influenza virus in the second or third trimester. Additionally, infants 27 
under six months of age are most vulnerable when contracting pertussis. Immunization 28 
against influenza and pertussis during pregnancy provides protection for mother and neonate 29 
against influenza and for neonates against pertussis pending protection through infant 30 
immunization. In Belgium, a gradual increase in pertussis cases over the past decade was 31 
observed. This study was undertaken to document vaccination coverage for influenza and 32 
pertussis and factors related to vaccination status in pregnant women. 33 
Methods: 250 pregnant women completed a questionnaire during their third trimester. 34 
Vaccination data were collected and reasons for non-vaccination were noted as well as socio-35 
demographic data which are known to influence vaccination coverage. 36 
Results: A documented vaccination coverage of 42.8% for influenza and 39.2% for pertussis 37 
was observed. Taking into account doses which were not documented, but administered 38 
according to the expectant mother, coverage for influenza would increase to 62% and for 39 
pertussis to 46%. The most important reasons for non-vaccination were the absence of a 40 
recommendation by medical staff (9.6%) and delay in vaccination (8.4%). The GP was the 41 
most important vaccinator. Pregnant women with a lower education and those with a foreign 42 
origin were more vulnerable for non-vaccination. 43 
Conclusion: Incomplete documentation is the most important barrier in determining the 44 
vaccination status of pregnant women. Immunization during pregnancy needs further 45 
integration through vaccination campaigns aimed at both health care providers and pregnant 46 
women.  47 
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Abbreviations:  50 
GP General Practitioner 51 
HCP Health Care Provider 52 
 53 
Highlights: 54 
• 42.8% of pregnant women had immunization records for influenza and 39.2% for 55 
pertussis, while only  23.6% had documentation for both vaccines. 56 
• The coverage increases to 62% for influenza and 46% for pertussis when oral 57 
communication was considered in addition. 58 
• Obstetricians and GP are most influential in decision of pregnant women to vaccinate. 59 
• Women with a low education and those of foreign origin are more vulnerable for non-60 
vaccination. 61 
 62 
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Introduction  64 
Insights in the burden of disease of influenza in pregnant women and studies on the 65 
resurgence of pertussis with a particular burden of disease in neonates have increased 66 
knowledge and awareness regarding the necessity of immunization of pregnant women 67 
against influenza and pertussis.[1-3]  68 
Pregnant women are at increased risk of severe complications and hospitalization when 69 
infected with influenza. Physiologic changes in the respiratory, cardiovascular and immune 70 
system during pregnancy may contribute to this increased risk [4-6]. In addition, pregnant 71 
women who are infected with influenza have an increased risk of adverse pregnancy 72 
outcomes such as preterm delivery, small-for-gestational-age infants, lower birth weight 73 
babies, and stillbirths [7-9].  74 
Since 2000, there is an increase in cases of pertussis in countries which have used the 75 
acellular pertussis vaccine for infant vaccination, including Belgium[10-11]. In particular 76 
newborns under 6 months of age are extremely vulnerable and the highest burden of disease 77 
occurs in this age group [11]. Infants need at least three doses of acellular pertussis vaccines 78 
to gain protection against pertussis by six months of age [12-13]. During the first months of 79 
life, maternal antibodies provide primary protection against infectious agents, as the neonate 80 
immune system cannot yet elicit adult-like humoral immune responses [14]. Therefore, the 81 
main reason to recommend pertussis vaccination during pregnancy is to elicit maternal 82 
antibodies in order to protect newborns during the first 6 months after birth [13].  83 
Inactivated influenza vaccines and combined diphtheria-tetanus-acellular pertussis vaccines 84 
are considered to be safe when given during pregnancy [2,4-6,15-17]. Studies on 85 
effectiveness on reducing influenza in pregnant women and neonates [1,18-19] and pertussis 86 
in neonates have shown the added value of immunizing pregnant women [11,20,21]. In 2012 87 
the World Health Organization (WHO) recommended immunization against seasonal flu for 88 
pregnant women[22] and in 2014 the Strategic Advisory Group of Experts (SAGE) considered 89 
that maternal immunization against pertussis was the most cost-effective complementary 90 
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strategy to prevent pertussis-associated infant mortality [23]. The Belgian Superior Health 91 
Council also recommends influenza vaccination in pregnant women from the second trimester 92 
of pregnancy onwards during the flu season [24]. In 2012, a new action plan regarding 93 
influenza vaccination was launched in Flanders, which considers pregnant women to be a 94 
specific target group, and aims at a coverage of at least 50% of all pregnant women by 2020 95 
[25]. Additionally, all pregnant women are also advised to be immunized against pertussis 96 
between 24–32 weeks of each pregnancy, regardless of whether they received a booster 97 
vaccine in the past or not [12]. 98 
Data on the combined vaccination coverage rate of influenza and pertussis in pregnant women 99 
are limited. This article reports the documented vaccination coverage of influenza and 100 
pertussis in pregnant women and possible associated socio-demographic factors for (non-101 
)vaccination. 102 
103 
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Material and methods 104 
Population and Sampling Procedure 105 
During the influenza season (December 2013 – February 2014), 257 women in their third 106 
trimester of pregnancy (≥ 28 weeks) attending the University Hospitals KU Leuven, Belgium 107 
for a routine third trimester ultrasound examination, were approached to participate in the 108 
study. Seven (2.8%) woman refused, mainly because of language barrier or lack of time, 109 
leaving questionnaires of the remaining 250 pregnant women fit for analysis. All participants 110 
were Belgian residents. 111 
 112 
Survey Procedure 113 
Potential participants were informed about the aim and course of the study by one of the 114 
authors. Upon agreement, they were asked to sign the informed consent, and a questionnaire 115 
was taken. The questionnaire was based on the questionnaire of the 2008-2012 Flemish 116 
coverage study in young children and adolescents, but adjusted for the current target group 117 
[26]. The questionnaire and informed consent were available in Dutch, French and English 118 
language to include as many patients as possible. 119 
The main part of the survey regarded data on influenza and pertussis vaccination: by whom 120 
they were informed or advised on vaccination in pregnancy, vaccination status and, if 121 
applicable, date and vaccinator, prior vaccination against influenza and pertussis, willingness 122 
to vaccinate their child, and vaccination status of the partner. The questionnaire included 123 
several items on socio-demographic background of the participant and her partner (Table 1). 124 
Obstetric data consisted of gestational age, obstetric history, parity, complications during 125 
pregnancy (bleeding, preterm contractions, hyperemesis gravidarum, gestational diabetes, 126 
gestational hypertension, infectious diseases and preeclampsia) and medical conditions 127 
(diabetes mellitus, cardiopathy, nephropathy, pulmonary condition, immune deficiency). 128 
Only documented vaccination data were taken into account. If not available, the hospital 129 
medical files or Vaccinnet, the Flemish vaccination registry, were checked. Finally, the GP of 130 
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the participant was contacted to provide still missing data. Data files were anonymised prior 131 
to analysis. 132 
 133 
Definitions for valid immunizations 134 
Valid immunization for influenza was defined as one dose of inactivated influenza vaccine 135 
since October 2013 after 12 weeks of pregnancy [24]. The recommendation for pertussis 136 
during pregnancy is one dose of dTap (Boostrix®). All vaccinations after 12 weeks of 137 
pregnancy were considered valid even though the recommended timing for this vaccine is 138 
between 24 and 32 weeks of gestation [12]. 139 
 140 
Ethical Approval 141 
The study protocol, questionnaire, and informed consent were approved by the Committee of 142 
Medical Ethics of the University Hospital of the KU Leuven. Guidelines of Good Clinical 143 
Practice and the Belgian law and local regulations were respected. 144 
 145 
Statistical Analysis 146 
A sample size of 250 subjects was proposed to obtain a confidence interval width of 147 
approximately 10 percentage points for a coverage rate between 10 and 50%. Estimates of 148 
the coverage rates are presented with a 95% confidence interval. Statistical significance of 149 
the effect of determinants on coverage rates was tested for each vaccine independently by 150 
univariate logistic regression. A test probability of 5% was considered statistically significant. 151 
Data were entered in Microsoft Access 2010, and R. version 3.0.2. (R Foundation for 152 
Statistical Computing, Vienna, Austria, 2013) was used for the statistical analysis. 153 
154 
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Results 155 
Study population 156 
Baseline characteristics of the study population are listed in table 1. Baseline characteristics 157 
of the partners were similar compared to pregnant women, except for a slightly older age (35% 158 
was over 35 years of age) and more often having a full-time job (91.3%). Most participants 159 
were aged between 25-34 years (70.8%), 78.0% were 28 to 32 weeks pregnant, 45.6% were 160 
primiparae, and 2% were pregnant of twins. Complications occurred in 12.8% of pregnancies. 161 
Most common complications were hyperemesis gravidarum (4.0%), bleeding (2.8%) and 162 
preterm contractions (2.8%). Twenty (8.0%) women had a medical condition which could give 163 
an increased risk when contracting influenza. All data on our study population were in line with 164 
census data on pregnant women in Flanders, except for a lower prevalence of gestational 165 
diabetes and hypertension.[27] 166 
 167 
Vaccination coverage 168 
 169 
In our study population, the documented vaccination coverage rate was 42.8% (n=107 - 95% 170 
CI: 36.6%-49.2%) for influenza, and 39.2% (n=98 - 95%CI: 33.2%-45.6%) for pertussis. 171 
Documentation for both vaccines was available in 59 women (23.6% - 95% CI: 18.6-29.5%). 172 
However, for many women who reported being immunized during the interview no 173 
documentation could be retrieved. Vaccination data for influenza were provided by 62 174 
pregnant women, for 27 women, data on flu vaccination were retrieved from the hospital 175 
medical records and 18 dates on flu vaccination by the general practitioner of the participants. 176 
For pertussis, 53 vaccination dates were obtained from the pregnant women directly, 18 were 177 
retrieved from the hospital medical records, 18 provided by the GP and 9 dates were found in 178 
Vaccinnet. When all information on both documented and undocumented vaccine doses, are 179 
taken into account, coverage rates increase to 62.0% for influenza and  to 46.0% for pertussis. 180 
For women who received both vaccines, the coverage would increase to 34.4%. Women with 181 
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an underlying medical condition had a significantly higher vaccination coverage for both 182 
influenza (45.0% vs 38.7%; p<0.05) and pertussis (45.0% vs 42.6%; p<0.01).  183 
 184 
Vaccinator 185 
For influenza, 63.2% of vaccinated women received the vaccine from their GP, 27.7% 186 
received the vaccine at work from the occupational medical officer and 9% received the 187 
vaccine from an obstetrician. For pertussis, 75.9% of vaccinated woman received the vaccine 188 
from the GPs, 20.5% from an obstetrician, and 3.6% at work. 189 
 190 
Reasons for vaccination 191 
Reasons given for vaccination were highly similar for influenza and pertussis (Table 2).  192 
In those who were not vaccinated against influenza, 24 (9.6%) cited the absence of a 193 
recommendation from their GP or obstetrician as main reason. For pertussis, 32 women 194 
(12.8%) cited pertussis vaccination during a previous pregnancy as reason for not being 195 
vaccinated. 196 
 197 
Socio-demographic determinants of vaccination status 198 
Potential socio-demographic determinants of the expectant mother and her partner are 199 
presented in Table 3. Age and work situation of the women and their partner, marital status or 200 
family income did not influence coverage rates for influenza or pertussis. 201 
Coverage rates were significantly higher in women of Belgian origin compared to women of 202 
European (other than Belgian, p<0.05) and non-European origin (p<0.01), except for pertussis 203 
in European women. Comparable results were obtained for the origin of the partner. 204 
Influenza coverage rates were higher in higher educated women (p<0.01) and partners 205 
(p<0.001), but no significant differences were found for pertussis.  206 
Women previously vaccinated against influenza had a higher vaccination rate during the 207 
current pregnancy (62.2% vs 37.8%), but this did not reach statistical significance due to the 208 
small number of subjects (n = 45) for whom this information was available (p=0.1). On the 209 
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contrary, out of 32 women who were vaccinated against pertussis during a previous pregnancy 210 
against pertussis, only 7 (21.9%) were revaccinated during the current pregnancy. Women of 211 
whom the partner recently received a pertussis vaccine, had also a significant higher coverage 212 
(47.7% vs 33.6%) (p<0.001). Almost 97% (n=242) of the participants intended to comply with 213 
Belgian recommendations for infant immunization, regardless of whether they received the 214 
pertussis vaccine or not.  215 
 216 
Information about vaccines 217 
Of the 250 women surveyed, 173 (69.2%) were aware of vaccination campaigns for pregnant 218 
women, 188 (75%) received information about flu vaccination, and 183 (73.2%) received 219 
information on pertussis vaccination. Vaccination coverage was higher in women who 220 
received information on influenza vaccination (50.5% vs. 19.3% - p<0.001) and pertussis 221 
vaccination (50.8% vs. 7.5% - p<0.001). For influenza vaccination, receiving information from 222 
the GP had the highest impact (60.6% coverage) compared to 47.1% if information was given 223 
by the obstetrician and 50.0% by midwife. Information on pertussis provided by an obstetrician 224 
resulted in a higher coverage (56.6%) compared to information given by a midwife (55.6%) or 225 
GP (44.9%). 226 
  227 
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Discussion 228 
This study is one of few surveys studying the coverage rates and influencing factors of both 229 
influenza and pertussis immunization during pregnancy. The documented coverage rate 230 
among pregnant women was 42.8% for influenza and 39.2% for pertussis. In comparison to 231 
other countries for which coverage rates in pregnant women are available these rates are 232 
acceptable, given the fact that recommendations are fairly recent. However, the goal of 50% 233 
documented influenza vaccination coverage set by the Flemish government in 2012 has not 234 
yet been reached [25]. The coverage rate for pertussis is lower compared to influenza, but 235 
information campaigns to stimulate immunization of pregnant women have mainly focussed 236 
on influenza, whereas the recommendation for vaccination against pertussis is more recent. 237 
Since the recent increase in pertussis cases in the general population as well as in children 238 
below one year of age, the Flemish community has started a campaign to raise awareness for 239 
pertussis vaccination during pregnancy for pregnant women and treating physicians such as 240 
GPs and obstetricians. 241 
Vaccination against influenza in pregnant women seems to increase worldwide. Studies in 242 
Australia partially confirmed this positive trend with coverage rates of 30% in 2010, 40% in 243 
2011 (Melbourne) [28] but the coverage dropped to 25% in 2012 (Sydney) [29]. Studies in the 244 
US showed similar trends with coverage rates of 38% in 2008-2009 and 63% in 2011-2012 245 
[30]. 246 
In Europe, data on the vaccination coverage during pregnancy is limited, as only one study 247 
from the UK was published, in which the coverage varied between 14.9% and 21.6% for 248 
influenza [31]. 249 
Intentions of pregnant women to accept vaccination in pregnancy are more frequently 250 
recorded. Varan et al reported that 57% of Mexican pregnant women were willing to accept a 251 
pertussis vaccine if offered, and over 80% would accept it if recommended by an obstetrician. 252 
However, only 16% had ever heard of pertussis [32]. An Australian study confirmed this trend 253 
for pertussis [33]. In our study, the main reasons cited for receiving the influenza vaccine 254 
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during pregnancy were recommendation by a health care provider (HCP), to protect the baby, 255 
to prevent influenza and information from friends, media and family. Reasons given for not 256 
being vaccinated against influenza are safety concerns regarding the unborn child and the 257 
lack of information or recommendation. Our data thus confirm concerns regarding vaccination 258 
given by pregnant women worldwide [18,27,32-36]. A large number of studies on the safety 259 
of influenza and pertussis immunization during pregnancy published to date show no evidence 260 
for an increase in adverse reactions in pregnant women or their offspring, nor an adverse 261 
outcome of pregnancy for either vaccine.[2,3,15-20] Even though the vaccination coverage 262 
for pertussis was lower compared to influenza, the reasons for not being vaccinated were 263 
similar for both vaccines. Also, there is no evidence that mothers in our study prioritised 264 
protection of the baby over their own protection as was shown in a recent on behaviours and 265 
attitudes of pregnant women towards vaccination [37]. Nevertheless, yearly influenza 266 
vaccination is well established, whereas booster vaccines for pertussis, particularly the 267 
recommendation of a booster during every pregnancy, is novel. This could explain why women 268 
who received a pertussis booster during a previous pregnancy were less likely to be 269 
vaccinated during the current pregnancy. 270 
The most important socio-demographic determinant of a lower vaccination coverage for both 271 
vaccines was the origin of participants and their partner, particularly in non-Europeans. This 272 
is in line with the factors that influence infant and adolescent vaccination coverage rates in 273 
Flanders, and is possibly due to a poor understanding of the local language, and the resulting 274 
difficulties to comprehend information on vaccinations given by HCPs [38].For influenza, a 275 
higher education of women and partners is associated with a higher coverage. This is probably 276 
due to better access to information on the vaccine and its advantages. In contrast, knowledge 277 
about the pertussis vaccination seems to be similar for every educational degree.  278 
As physicians are the most trusted source of information and their recommendation has the 279 
highest impact, the treating physician should take every opportunity to promote immunization 280 
against influenza and pertussis in pregnant women. Increased access to vaccination services 281 
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in non-traditional settings has been used as a strategy in pursuit of national vaccination 282 
coverage objectives in other countries [39]. For pregnant women, midwives could have an 283 
important role in giving information on immunization during pregnancy, since they monitor 284 
women during pregnancy. In our study, information given by midwives resulted in a higher 285 
vaccination coverage for both influenza and pertussis. However, midwives have also been 286 
instructed for many years to use as little medication as possible in pregnant women. Therefore 287 
reluctance to implement the recommendation regarding vaccination cannot be excluded, and 288 
additional training of midwives may be necessary to overcome these barriers and to promote 289 
vaccination during pregnancy. 290 
One other reason for the relatively low coverage rates in our study, could be that obstetricians 291 
recommended vaccination against influenza and pertussis, but do not administer the vaccines 292 
themselves. In Belgium, the GP is considered the primary vaccinator for adults, and pregnant 293 
women are therefore referred to their GP for vaccination. However, it has been shown that 294 
pregnant women whose HCPs both recommend and offer influenza vaccination are more 295 
likely to be vaccinated (73.6%) compared to those who only received a recommendation 296 
(47.9%) and those who received neither recommendation or offer (11.1%) [40]. Moreover, for 297 
pertussis it is important that vaccines during pregnancy are given prior to 32 weeks to reach 298 
higher titers of neonatal antibodies, which results in longer protection [41,42]. 299 
In this study only 250 participants were sampled in a single university hospital in Flanders. 300 
Further research in several Belgian hospitals is recommended to confirm whether these 301 
results can be extrapolated to the entire country. Another limitation is the large difference 302 
between documented and assumed coverage rates. Despite our efforts to trace written proof 303 
for all vaccines, this information could not be retrieved for all given doses. Therefore, the 304 
(documented) coverage rates presented here should be considered as a minimum. If oral 305 
communication on vaccination would be taken into account, coverage would increase to 62% 306 
for influenza and 46% for pertussis. We explicitly choose for a face-to-face survey because 307 
written and telephone surveys tend to overrate the actual vaccination coverage due to recall 308 
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bias [43,44]. It might be that for pregnant women recall bias is less applicable since recall is 309 
only necessary for the last 6 months. Nevertheless, immediate registration of all administered 310 
vaccines in the available electronic vaccination database would largely facilitate the retrieval 311 
of vaccination dates and thus increase the accuracy of future coverage estimates. A 312 
vaccination register, Vaccinnet, is in use since 1999 for the registration of community-based 313 
vaccination of infants and school-aged children by well-baby clinics and school health centers. 314 
Even though this register has since been open to Flemish inhabitants, registration of adult 315 
vaccination is still limited. From July 2014 onwards, one dose of the combined diphtheria-316 
tetanus-acellular pertussis vaccine is available free of charge for all adults (including pregnant 317 
women) on the condition that the vaccine is registered in Vaccinnet. This might improve the 318 
documented data on pertussis vaccination during pregnancy. A final limitation of our study is 319 
it was conducted during pregnancy and not after delivery. The survey itself could have 320 
triggered our study subjects to comply with recommendations, but this could not be measured 321 
with the present study design. A survey immediately after delivery might pick-up vaccines 322 
given after 32 weeks of pregnancy. 323 
A strength of this study was the high response (98%) and the fact that our population matched 324 
with census data. Only seven women refused to participate because of lack of time or a 325 
language barrier. Survey forms were available in different languages to maximize the 326 
response, and all participants were interviewed by only one of us (JL), which increased the 327 
consistency of the data. Moreover, all vaccination data were double-checked against medical 328 
files from the hospital or GP. 329 
To improve uptake of recommended vaccines in pregnant women, HCPs (obstetricians, GP’s 330 
and midwives) should receive clear guidelines and more information on the benefits and safety 331 
of vaccination during pregnancy. Based on the results of our study, special attention for 332 
women with a lower education or foreign origin is recommended.  333 
 334 
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Conclusion 335 
The documented vaccination coverage in pregnant women is 42.8% for influenza and 39.2% 336 
for pertussis, but only 23.6% received both vaccines. These estimates should be considered 337 
as a minimum, as only documented vaccination was taken into account. 338 
While counseling, treating physicians should pay special attention to vulnerable groups, such 339 
as pregnant women with a lower educational level and foreign origin. Midwives could be 340 
involved in informing pregnant women on the benefits of vaccination during pregnancy. 341 
Registration of all administered vaccines in the register could improve documented coverage 342 
rates. 343 
  344 
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Table 1: Characteristics of participants and current pregnancy 345 
 346 
Characteristic Pregnant women 
n=250 
 n (%) 
Age (years) 
  
< 25 19 (7.6) 
25-34 177 (70.8) 
≥ 35 54 (21.6) 
Origin1 
  
Belgian 191 (76.4) 
European 24 (9.6) 
Non-European 35 (14.0) 
Education2 
  
Lower education 29 (11.6) 
Secondary school (completed) 59 (23.6) 
Higher education (Bachelor, Master, PhD) 162 (64.8) 
Work Situation 
  
Job (full-time, independent) 146 (58.4) 
Part-time job 52 (20.8) 
No job (student, paid leave, 
housewife/man, disabled or job-seeking) 52 (20.8) 
Marital status 
  
Cohabiting 111 (44.4) 
Married 122 (48.8) 
Single 10 (4.0) 
Other 7 (2.8) 
Family income (euros)3 
  
< 1500 9 (3.6) 
1500 – 3000 73 (29.2) 
> 3000 131 (52.4) 
No data 37 (14.8) 
Gestational age (weeks) 
  
28 - 32 195 (78.0) 
> 32 55 (22.0) 
Parity 
  
First pregnancy 114 (45.6) 
Second pregnancy or higher parity 136 (54.4) 
Current pregnancy 
  
Singleton 245 (98.0) 
Twin 5 (2.0) 
Pregnancy complications 
  
No 218 (87.2) 
Yes 32 (12.8) 
Pre-existing medical condition 
  
No 230 (92.0) 
Yes 20 (8.0) 
1
 Origin: based on the country of origin of the women, their partners and their parents. If the woman or one or both 347 
parents was of non-Belgian origin then the subject was considered of non-Belgian origin. If the birth country 348 
was located within the 27 countries of the European Union, then the subject was assigned as European. All 349 
other countries were regarded as non-European. Similar classification was done for the partner. 350 
2 Education: lower education = no secondary school diploma; Secondary school = completed secondary school 351 
with diploma; Higher education = continued education beyond secondary school. 352 
3
 Family income was determined as the total amount of money available monthly that could be spent, including 353 
alimony, wages and social security allowance. 354 
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Table 2: Reasons cited for receiving or not receiving vaccination (several answers were possible) 356 
 357 
 Influenza 
N=250 
Pertussis 
N=250 
  
n (%) 
 
n (%) 
Reasons cited for receiving vaccination 
during pregnancy     
Obstetrician recommended it 89 (35.6) 83 (33.2) 
I want to protect my baby 82 (32.8) 77 (30.8) 
I want to protect myself 59 (23.6) 25 (10.0) 
GP recommended it 53 (21.1) 36 (14.4) 
I think all pregnant women should get it 9 (3.6) 13 (5.2) 
I normally get the influenza/pertussis 
vaccine 
8 (3.2) 8 (3.2) 
Information from family/friends/media 7 (2.8) 10 (4.0) 
High risk work environment 6 (2.4 11 (4.4) 
I want to prevent influenza/pertussis 5 (2.0) 7 (2.8) 
Other reasons 0 (0.0) 10 (4.0) 
 
    
Reasons cited for NOT receiving 
vaccination during pregnancy     
Vaccination was not recommended 24 (9.6) 30 (12.0) 
The vaccination was delayed 21 (8.4) 35 (14.0) 
I don’t believe vaccines are safe and 
effective 
17 (6.8) 11 (4.4) 
Other reasons 13 (5.2) 32 (12.8) 
Concerns about the safety for my baby 8 (3.2) 8 (3.2) 
An adverse reaction in the past 8 (3.2) 4 (1.6) 
Careless/oblivion 6 (2.4) 5 (2.0) 
Concerned about adverse reaction 6 (2.4) 1 (0.4) 
GP or obstetrician advised against it 3 (1.2) 2 (0.8) 
 358 
 359 
  360 
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Table 3: Influenza and pertussis vaccination coverage according to socio-demographic characteristics 361 
(univariate analysis) 362 
 363 
Characteristic 
Influenza  Pertussis 
Covera
ge 
(%) 
OR 95% CI  
Covera
ge 
(%) 
OR 95% CI 
Age (yrs) 
       
<25 21.1 0.33 (0.09–0.95)  31.6 0.78 (0.26-2.07) 
25-34 44.6    37.3   
≥35 44.4 0.99 (0.53-1.83)  48.1 1.56 (0.84-2.89) 
Marital status 
       
Cohabiting/Married 44.2    39.5   
Single 30.0 0.54 (0.11-2.00)  20.0 0.38 (0.06-1.57) 
Other 14.3 0.21 (0.1-1.26)  57.1 2.04 (0.44-10.57) 
Origin pregnant 
women 
  
Belgian 49.2    42.9   
European 20.8 0.27 (0.09-0.71)*  37.5 0.80 (0.32-1.88) 
Non-European 22.9 0.31 (0.12-0.68)**  20.0 0.33 (0.13-0.76)* 
 
       
Origin partner 
       
Belgian 48.7    43.5   
European 19.0 0.25 (0.07-0.70)* 
 28.6 0.52 (0.18-1.34) 
Non-European 23.1 0.32 (0.11-0.78)* 
 23.1 0.39 (0.14-0.96) 
 
       
Education 
pregnant women        
Low education 17.2 0.51 (0.15-1.49)  24.1 0.40 (0.14-1.05) 
Secondary school 
(completed) 28.8    44.1   
High education 
(Bachelor, Master, 
PhD) 
52.5 2.73 (1.46-5.29)** 
 40.1 0.85 (0.47-1.56) 
 
       
Education partner 
       
Low education 34.8 1.49 (0.53-4.00)  43.5 0.85 (0.33-2.18) 
Secondary school 
(completed) 26.3    47.4   
High education 
(Bachelor, Master, 
PhD) 
53.9 3.27 (1.80-6.12)*** 
 35.5 0.61 (0.35-1.08) 
 
       
Work pregnant 
women 
       
Job (full-time or 
independent) 46.6    41.8   
Part-time job 40.4 0.78 (0.40-1.47)  42.3 1.02 (0.53-1.93) 
No job (student, 
paid leave, 
housewife, disabled 
or job-seeking) 
34.6 0.61 (0.21-0.93)  30.0 0.56 (0.28-1.10) 
 
       
Work partner 
       
Job (full-time, part-
time or 
independent) 
44.5    40.6   
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Logistic regression: *p<0.05; **p<0.01; p<0.001 364 
 365 
  366 
No job (student, 
paid leave,  
houseman, 
disabled or job-
seeking) 
18.2 0.28 (0.04-1.10)  27.3 0.55 (0.12-1.95) 
 
       
Income (euros) 
       
< 1500 22.2 0.46 (0.07-2.06)  22.2 0.55 (0.08-2.47) 
1500-3000 38.4    34.2   
> 3000 50.4 1.63 (0.91-2.94)  43.5 1.48 (0.82-2.70) 
No data 29.7 0.68 (0.28-1.56)  37.8 1.17 (0.51-2.65) 
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